Cite
MLA Citation
Radhakrishnan Ramchandren et al.. “The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study.” EClinicalMedicine, vol. 56, 2023, p. . http://access.bl.uk/ark:/81055/vdc_100179406317.0x000005